Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
Ab209871-100μg
|
100μg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$109.90
|
|
|
Ab209871-1mg
|
1mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$509.90
|
|
|
Ab209871-5mg
|
5mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$1,399.90
|
|
|
Ab209871-10mg
|
10mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$2,299.90
|
|
Purity≥95% (SDS-PAGE&SEC-HPLC); Endotoxin Level<1.0 EU/mg; Human IgG1; CHO; ELISA, Flow Cytometry, Functional assay, Animal Model; Unconjugated
| Product Name | Novartis patent anti-PMEL17 (anti-PMEL) - Primary antibody, specific to PMEL |
|---|---|
| Synonyms | 95 kDa melanocyte specific secreted glycoprotein antibody | 95 kDa melanocyte-specific secreted glycoprotein antibody | D12S53E antibody | gp100 antibody | M-beta antibody | ME20 antibody | ME20 M/ME20 S antibody | ME20-M antibody | ME20-S antibody | ME20 |
| Specifications & Purity | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA |
| Biochemical and Physiological Mechanisms | Plays a central role in the biogenesis of melanosomes. Involved in the maturation of melanosomes from stage I to II. The transition from stage I melanosomes to stage II melanosomes involves an elongation of the vesicle, and the appearance within of distin |
| Host species | Human |
| Specificity | PMEL |
| Conjugation | Unconjugated |
| Grade | Animal Free, Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Product Description |
Novartis patent anti-PMEL17 (anti-PMEL) is a monoclonal antibody targeting human PMEL protein. It is used as a target for antibody drug conjugate (ADC) therapy in melanoma. |
| Light Chain Type | lambdaC2 |
|---|---|
| SDS-PAGE | 145.38 kDa |
| Purification Method | Protein A purified |
| Concentration | See COA |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle. |
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Novartis patent anti-PMEL17 (anti-PMEL) (Ab209871) - Flow Cytometry
Flow Cytometry analysis of pLVX-puro-CRS-hu-PMEL-FL cells labelling PMEL at 1×105 cell/well can bind Novartis patent anti-PMEL17 (anti-PMEL) (Ab209871), with the EC50 is 0.16 nM.
Novartis patent anti-PMEL17 (anti-PMEL) (Ab209871) - SEC
The purity of Novartis patent anti-PMEL17 (anti-PMEL) (Ab209871) is more than 95% verified by HPLC.
Starting at $109.90